DESI drug compliance policy guide
This article was originally published in The Tan Sheet
FDA announces draft compliance policy guide Oct. 17 for drugs that were subject to the Drug Efficacy Study Implementation program and are marketed without an approved NDA or ANDA. Guide outlines FDA policies to encourage companies to sponsor drugs through the approval process. Document also describes for public comment the agency's enforcement approach, which gives highest priority to products that pose the most likely risk to public safety, either because of inherent safety concerns or because there are alternative, FDA-approved treatments available, the agency said. Development of guide was prompted by petition from a group of manufacturers and distributors of Rx extended-release guaifenesin, which have been directed by FDA to remove their products from the market because they have not cleared the approval process (1"The Tan Sheet" March 3, 2003, p. 4)...
You may also be interested in...
Single-ingredient, extended-release prescription guaifenesin products must be removed from the market by the end of November if they have not been approved by FDA, the agency states in Feb. 25 letters to 66 marketers and distributors of the drugs
The AAM has warned the Trump administration that ‘Buy American’ requirements on medicines could limit patient access to affordable medicines and increase the risk of drug shortages during the coronavirus pandemic.
The US agency has pushed to next month a public meeting on the latest incarnation of the Medical Device User Fee Amendments. The meeting will be held remotely.